middle.news
Immutep’s Efti Combo Sparks Hope for Tough-to-Treat Lung Cancer Patients
8:27am on Monday 20th of October, 2025 AEDT
•
Healthcare
Read Story
Immutep’s Efti Combo Sparks Hope for Tough-to-Treat Lung Cancer Patients
8:27am on Monday 20th of October, 2025 AEDT
Key Points
Eftilagimod alfa (efti) combined with KEYTRUDA and chemo achieves 61.7% response in low/no PD-L1 NSCLC
INSIGHT-003 trial data outperform historical controls across all PD-L1 expression levels
TACTI-004 Phase III trial underway to confirm efficacy in 756 global patients
Efti’s mechanism activates both adaptive and innate immunity for broader cancer response
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE